

CLAIMS

Claim 1. Use of an antibody against calnexin (Cnx) in the manufacture of a medicament for the treatment of cancer, wherein the antibody inhibits Cnx and antibody-mediated inhibition of Cnx reduces or inhibits tumor growth.

5 Claim 2. The use according to claim 1, in which the cancer comprises invasive or metastatic cancer.

 Claim 3. The use according to claim 2, wherein the medicament is for the treatment or prevention of metastasis.

 Claim 4. The use according to any one of claims 1 to 3, in which the cancer is
10 characterised by elevated levels of O-glycosylation.

 Claim 5. The use according to claim 4, wherein the cancer is characterised by elevated levels of endoplasmic reticulum (ER) O-glycosylation, or elevated levels of O-glycosylation of Cnx.

 Claim 6. The use according to claim 4 or 5, wherein the cancer is selected from the
15 group consisting of: liver, breast, sarcoma, lung, prostate, bladder, kidney, melanoma, pancreatic, endometrial, colorectal and thyroid cancer.

 Claim 7. The use according to any previous claim, wherein the antibody is monoclonal.

 Claim 8. The use according to any previous claim, wherein the antibody is
20 humanised.

 Claim 9. The use according to any preceding claim, in which the antibody against Cnx is an Fv, F(ab') and F(ab')₂, or scFv antibody.